Trial Profile
A 12-Week Open-Label Non-Interventional Evaluation of Atacand (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2012
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Feb 2009 New trial record